Author Archives: Millie Nelson

CytomX and Moderna partner to develop mRNA-based therapeutics

CytomX Therapeutics will combine its Probody platform with Moderna’s mRNA technology to create and advance therapeutics for oncology and non-oncology conditions. The partnership and licensing agreement, which aims to generate investigational messenger RNA (mRNA) based conditionally activated therapies, will use Moderna’s mRNA technologies alongside CytomX’s Probody therapeutic platform. According to CytomX, its platform enables proteins to activate in diseased tissue while remaining masked in systemic circulation, expanding the availability of new targets for the potential treatment of a large range…

Patient access is political, say CGT experts

Payment models for cell and gene therapies must consider how healthcare systems operate to accommodate patient access, say experts. While the cost of gene therapies is often debated throughout the life sciences space, a panel discussion at Cell and Gene Manufacturing and Commercialization (CGMC) in Amsterdam, The Netherlands last month highlighted that the discussion of innovative payment models must also include cross border healthcare patients and payments. Francis Pang, senior vice president of market access and geographical expansion at Orchard…

MaxCyte signs electroporation deal with Catamaran

Catamaran Bio will have non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electroporation technology and ExPERT platform. MaxCyte has signed a strategic platform licence (SPL) with Catamaran, a company focused on developing off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cell therapies used to treat a wide range of cancers, particularly solid tumors. While financial details of this deal remain undisclosed, MaxCyte has confirmed it will receive platform licensing fees and program-related revenue under the terms of the agreement. “The…

Sartorius and RoosterBio extend stem cell production partnership

The extended collaboration sees Sartorius and RoosterBio aim to commercialize exosome production and purification processes using various technologies.  The partnership between Sartorius and RoosterBio began almost two years ago. The firms teamed up to find ways of scaling-up production of stem cell-based regenerative therapies and combined Rooster’s human mesenchymal stem/stromal cell (hMSC) working cell banks and media systems with Sartorius’ single-use manufacturing tech, process control software and analysis tools. Now, both parties say the extended partnership looks to “take a…

Podcast: From platform to patient, CGTs must be more accessible

We sit down with Ori Biotech’s CEO Jason Foster to discuss the company’s paperless platform journey to commercialization and to delve deep into the challenges associated with accessing advanced therapies. This episode of the BioProcess Insider Expression Platform (BIEP) podcast brings you an in-depth conversation with Jason Foster, CEO of Ori Biotech. The company experienced a year of transition in 2022 with the closing of its $100 million Series B funding round and the expansion of its paperless cell and…

Moderna makes first-ever acquisition with $85m OriCiro buy

Moderna says the acquisition of Japan-based OriCiro will provide it with the tools needed for cell-synthesis and amplification of plasmid DNA. Moderna will buy OriCiro Genomics, a company founded in 2018 that focuses on cell-free DNA synthesis and amplification technologies, for $85 million, bolstering its messenger RNA (mRNA) technology offering. OriCiro is Moderna’s first acquisition since the company launched in 2010. The deal  comes two years after the success of its cell-free COVID-19 vaccine, mRNA-1273, which received emergency use authorization (EUA)…

Recipharm warns of fill/finish competition as COVID-19 vax demand dwindles

There is significant market demand for global sterile capacity says Recipharm. But as the need for COVID-19 vaccine filling decreases, competition between CDMOs will rise. Swedish contract development manufacturing organization (CDMO) Recipharm has made various investments across the globe to strengthen its fill-finish capabilities and capacity. In October, the firm scaled up its sterile filling capabilities by investing in Lab+ technology used for low volume blow-fill-seal (BFS) filling at its plant in Kaysersberg, France. Furthermore, the CDMO signed a Memorandum…

Ferring gets FDA greenlight for bladder cancer gene therapy

The US Food and Drug Administration (FDA) has approved Ferring Pharmaceuticals’ adenovirus vector-based gene therapy, Adstiladrin (nadofaragene firadenovec-vncg). Adstiladrin is an intravesical therapy administered to the patient at three-month intervals. The therapy is used to treat adults with high-risk Bascillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) that works by targeting the individuals’ bladder wall cells to boost the body’s natural defenses to fight cancer. According to the firm, the FDA approval is based on positive Phase III clinical trial…

ReiThera supports Sabin’s Ebola Sudan vax production

ReiThera is manufacturing the drug substance for Sabin Vaccine Institute’s ChAd3 Ebola Sudan vaccine and performing fill/finish for the first 9,600 doses. Contract development manufacturing organization (CDMO) ReiThera will produce Sabin’s ChAd3 (chimpanzee adenovirus) Ebola Sudan single-dose vaccine at its Castel Romano Technopole plant, Italy, which it opened in November. ReiThera claims Sabin is the first organization to provide the World Health Organization (WHO) its Ebola Sudan vaccine to support the Ebola Sudan outbreak in Uganda.  Around 1,100 doses of Sabin’s vaccine…

Lets review 2022 – BioProcess Insider’s Big M&A of the Year!

As the year draws to a close, BioProcess Insider brings you our Christmas quiz special where we test your 2022 M&A knowledge. 2022 has been a year full of M&A activity, some with big price tags and others that have seen companies move into different modalities and service offerings. BioProcess Insider wanted to bring our readers some festive fun ahead of Christmas and the New Year. Happy Christmas from Bioprocess Insider and here’s to another year full M&A activity!   Loading…